Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Sumon Roy und 5 weiteren Autor:innen. Beteiligte Einrichtung: McGuire Veterans Administration Medical Center, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Coronary Angiography, Cardiac Catheterization, Coronary Artery Disease. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long‐term outcomes in patients with cardiovascular disease are not well understood.
Objective
We studied the association between PDE5 inhibitor therapy and the incidence of adverse cardiovascular major adverse cardiovascular events (MACE) in patients undergoing coronary angiography and intervention.
Methods
We studied 4582 consecutive patients undergoing coronary angiography and intervention. The incidence of MACE at 1 year, defined as urgent revascularization, myocardial infarction, admission for heart failure or all‐cause death, was considered the primary outcome.
Results
Of the 4582 patients, 562 (12.3%) had current prescriptions for PDE5 inhibitors before the procedure and 4020 (87.7%) did not. The incidence of MACE was 171 (30.4%) among patients of the PDE5 inhibitor group versus 1482 (36.9%) in the non‐PDE5 inhibitor group ( p = 0.003). In a propensity score‐matched analysis of 1124 of patients, 171 (30.4%) patients in the PDE5i group and 175 (31.1%) patients in the non‐PDE5i group had a MACE ( p = 0.84). On multivariable analysis, the treatment with PDE5 inhibitors was not significantly associated with the risk of MACE (odds ratio [OR] = 0.99, 95% CI 0.93–1.06; p = 0.86).
Conclusion
In this cohort of veterans undergoing coronary angiography/cardiac catheterization, chronic PDE5i therapy was not associated with an increased risk of MACE at 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McGuire Veterans Administration Medical Center, Richmond, Virginia, USA.
- Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Sumon Roy, Annette Min, Ion S Jovin
Förderung
- NHLBI NIH HHS
- The authors received no specific funding for this work.
Zitieren
APA
Roy, S., Min, A., McFalls, E. O., Perera, R. A., Salloum, F. N., & Jovin, I. S. (2025). Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31624
Vancouver
Roy S, Min A, McFalls EO, Perera RA, Salloum FN, Jovin IS. Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31624
BibTeX
@article{Roy2025,
author = {Roy, Sumon and Min, Annette and McFalls, Edward O and Perera, Robert A and Salloum, Fadi N and Jovin, Ion S},
title = {Treatment With Phosphodiesterase 5 Inhibitors and Long‐Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31624}
}
EUVIMED